issues affecting payer uptake and provider adoption of biosimilars in the US, such as economic considerations, clinical evidence, and market

According to interviewed experts at IPD Analytics, the 2020 drug pipeline includes a large number of generic launches.

The pace of clinical trials have been affected by COVID-19, according to IPD Analytics' experts on the pharmaceutical pipeline.